Author  
Place of duty  
Title   진행비소세포성 폐암환자에서의 Cisplatin 단독화학요법 및 PEV ( Cisplatin , Etoposide , Vinblastine ) 복합화학요법의 치료효과에 관한 제 3 상 비교연구 ( A Prospective Randomized Study of Cisplatin versus PEV ( Cisplatin , Etoposide , Vinblastine ) Chemotherapy in Advanced Non - Small Cell Lung Canc
Publicationinfo   1992 Jan; 024(02): 256-268.
Key_word   Non-small cell luna cancer, Chemotherapy
Full-Text  
Abstract   One hundred and twenty-seven patients with unresectable non-small cell lung cancer were included in a randomized trial comparing the activity of cisplatin as a single agent with the combination of cisplatin, etoposide, and vinblastine(PEV). All patients were previously untreated and prognostic factors(performance status, weight loss, extent of disease, and histology) were evenly distributed between two study groups. In 115 evaluable patients(54 for cisplatin alone and 61 for combined regimenL the only complete responder was PEV combination(p=0.051). The median time to progression for patients treated with cisplatin alone was 22 weeks, which was significantly longer than 13 weeks for patients treated with PEV regimen(p =0.0001). No statistically significant difference in survival was observed between the Patients treated with cisplatin alone and those treated with combined regimen(median survival; 8 v 11 months). In the PEV arm, the median survival was 14 months for patients with ECOG per- formance status of O-l, compared with 3.4 months for those with ECOG performace status of 2 (p = 0.000 I ), and 14 months for patients without previous weight loss, compared with 8.4 months for those with previous weight loss(p=0.04). Myelosuppression was greater with the combination, but with regards to non-hematologic toxicity, there was no significant difference between two arms except for alopecia which occured more frequently in patients treated with combined regimen. The results indicate that the combination of cisplatin, etoposide, and vinblastine is superior to cisplatin alone in terms of response rate and the time to progression in non-small cell lung cancer, but confers no significnt survival advantage compared with cisplatin alone in spite of greater degree of myelosuppression.
저 자   이기형(Ki Hyeong Lee),강원기(Won Ki Kang),장정순(Joung Soon Jang),윤성주(Sung Soo Yoon),임영택(Uoung Hyuk Im),이재용(Jae Yong Lee),박영석(Young Suk Park),서창인(Chang In Suh),허대석(Dae Seog Heo),방영주(Yung Jue Bang),심영수(Young Soo Shim),김노경(Noe Kyeong Kim),김건열(Keun Youl Kim),한용철(Yong